Title
|
|
|
|
Impact of domiciliary administration of NSAIDs on COVID-19 hospital outcomes : an unCoVer analysis
| |
Author
|
|
|
|
| |
Abstract
|
|
|
|
Background: Effective domiciliary treatment can be useful in the early phase of COVID-19 to limit disease progression, and pressure on hospitals. There are discrepant data on the use of non-steroidal anti-inflammatory drugs (NSAIDs). Aim of this study is to evaluate whether the clinical outcome of patients who were hospitalized for COVID-19 is influenced by domiciliary treatment with NSAIDs. Secondary objective was to explore the association between other patient characteristics/therapies and outcome.Methods: A large dataset of COVID-19 patients was created in the context of a European Union-funded project (unCoVer). The primary outcome was explored using a study level random effects meta-analysis for binary (multivariate logistic regression models) outcomes adjusted for selected factors, including demographics and other comorbidities.Results: 218 out of 1,144 patients reported use of NSAIDs before admission. No association between NSAIDs use and clinical outcome was found (unadj. OR: 0.96, 95%CI: 0.68-1.38). The model showed an independent upward risk of death with increasing age (OR 1.06; 95% CI 1.05-1.07) and male sex (1.36; 95% CI 1.04-1.76).Conclusion: In our study, the domiciliary use of NSAIDs did not show association with clinical outcome in patients hospitalized with COVID-19. Older ages and male sex were associated to an increased risk of death. |
| |
Language
|
|
|
|
English
| |
Source (journal)
|
|
|
|
Frontiers in pharmacology. - [Lausanne, 2010, currens
| |
Publication
|
|
|
|
[Lausanne
:
Frontiers Media]
,
2023
| |
ISSN
|
|
|
|
1663-9812
| |
DOI
|
|
|
|
10.3389/FPHAR.2023.1252800
| |
Volume/pages
|
|
|
|
14
(2023)
, p. 1-5
| |
Article Reference
|
|
|
|
1252800
| |
ISI
|
|
|
|
001087430800001
| |
Pubmed ID
|
|
|
|
37876733
| |
Medium
|
|
|
|
E-only publicatie
| |
Full text (Publisher's DOI)
|
|
|
|
| |
Full text (open access)
|
|
|
|
| |
|